Eikon Therapeutics, Inc.
EIKN$783M
Small CapNASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
6
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Dec 15, 2026
39wMarket Overview
Stock performance and key metrics
EIKN News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
EIK1001
Advanced Melanoma
EIK1004-001 (IMP1707-001)
Advanced Solid Tumors
IMP1734
Advanced Solid Tumor
EIK1005
Advanced Solid Tumors
Paclitaxel
NSCLC
BDB001
Tumor, Solid
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EIK1001 | Phase 3 | Advanced Melanoma | - | - |
EIK1004-001 (IMP1707-001) | Phase 2 | Advanced Solid Tumors | - | - |
IMP1734 | Phase 2 | Advanced Solid Tumor | - | - |
EIK1005 | Phase 2 | Advanced Solid Tumors | - | - |
Paclitaxel | Phase 2 | NSCLC | - | - |
BDB001 | Phase 2 | Tumor, Solid | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply